The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 238 participants.
Also called NCT02433119
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 238 participants
- Sponsor
- Registry
-
NCT02433119
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02433119. Randomized; quadruple masking; primary purpose treatment. Start 2015-03-16 (actual); primary completion 2016-09-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy
- Condition
- Hypertension
- Intervention (Drug)
- OROSARTAN® 5/160mg
- Intervention (Drug)
- CODIOVAN® 160/12.5mg
- Lead sponsor
- Dong-A ST Co., Ltd.
Record details
- Record id
cardio:ct-nct02433119- Content hash
68c1faac552809b7c60fb0a8a12b4f76fe9b9963bfe1de5d15e88161f0c44188